Loading AI feed…
PepGen
Action, confidence, horizon, and decision blockers at a glance.
Fast scan of bull, bear, and watch items
High-level snapshot
Thesis highlights from the latest analysis
Scannable catalysts and supporting factors
Other notable items detected
Next few weeks
Months to a year
| Symbol | Summary |
|---|---|
| RNA | Avidity is a direct DM1 operating comparator because PepGen identifies del-desiran/AOC 1001 as a Phase 3 clinical program competing against PepGen's DM1 candidate, making RNA the clearest category benchmark for speed and perceived efficacy leadership [#10-K-2026-03-04]. |
| TRDA | Entrada is a direct DM1 peer because PepGen lists VX-670, developed with Vertex, as a Phase 2 DM1 program, giving PepGen a third clinically active same-indication comparator beyond the broader small-cap biotech universe [#10-K-2026-03-04]. |
Internal and external references used in this analysis